VistaGen Therapeutics - VTGN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $9.00
  • Forecasted Upside: 5,603.42 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.16
▼ -0.0048 (-2.95%)

This chart shows the closing price for VTGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New VistaGen Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VTGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VTGN

Analyst Price Target is $9.00
▲ +5,603.42% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for VistaGen Therapeutics in the last 3 months. The average price target is $9.00, with a high forecast of $9.00 and a low forecast of $9.00. The average price target represents a 5,603.42% upside from the last price of $0.16.

This chart shows the closing price for VTGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in VistaGen Therapeutics. This rating has held steady since December 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/26/2022Maxim GroupDowngradeBuy ➝ HoldLow
7/22/2022Robert W. BairdDowngradeOutperform ➝ NeutralLow
7/22/2022Jefferies Financial GroupDowngradeBuy ➝ HoldLow
7/22/2022William BlairDowngradeOutperform ➝ Market PerformLow
10/17/2021Robert W. BairdInitiated CoverageBuy$9.00High
8/15/2021Robert W. BairdReiterated RatingBuy$9.00Medium
5/19/2021Robert W. BairdInitiated CoverageOutperform$9.00High
2/18/2021Jefferies Financial GroupInitiated CoverageBuy$6.00High
1/4/2021William BlairUpgradeMarket Perform ➝ OutperformN/A
12/22/2020Maxim GroupBoost Target$3.00 ➝ $5.00Low
10/8/2020AegisInitiated CoverageBuy$6.00Low
8/11/2020Maxim GroupReiterated RatingBuy$3.00High
6/26/2020Maxim GroupReiterated RatingBuy$1.00Medium
5/29/2020Maxim GroupInitiated CoverageBuy$1.00High
4/29/2020Maxim GroupInitiated CoverageBuy$1.00Low
12/2/2019Chardan CapitalReiterated RatingNeutralHigh
11/14/2019William BlairDowngradeOutperform ➝ Market PerformHigh
11/3/2019Chardan CapitalReiterated RatingHold$0.70Low
10/15/2019Maxim GroupSet TargetBuy$4.00N/A
10/9/2019William BlairReiterated RatingBuyN/A
10/8/2019Maxim GroupSet TargetBuy$4.00Low
8/28/2019William BlairInitiated CoverageOutperformHigh
7/29/2019Chardan CapitalReiterated RatingNeutralHigh
7/22/2019Chardan CapitalDowngradeBuy ➝ Neutral$22.00 ➝ $0.70High
5/2/2019Maxim GroupSet TargetBuy$6.00High
3/6/2019Maxim GroupReiterated RatingBuy$6.00High
11/4/2018OppenheimerSet TargetBuy$6.00Medium
10/25/2018Maxim GroupSet TargetBuy$6.00Low
10/3/2018Maxim GroupSet TargetBuy$6.00High
9/13/2018Maxim GroupSet TargetBuy$6.00Medium
9/5/2018Maxim GroupSet TargetBuy$6.00Low
9/4/2018OppenheimerSet TargetBuy$6.00Low
8/30/2018Maxim GroupSet TargetBuy$6.00High
8/24/2018OppenheimerSet TargetBuy$6.00Low
8/14/2018Maxim GroupSet TargetBuy$6.00High
8/6/2018Maxim GroupSet TargetBuy$6.00Low
6/29/2018Chardan CapitalReiterated RatingBuy$22.00Medium
6/27/2018Maxim GroupInitiated CoverageBuy$6.00Low
5/24/2018OppenheimerInitiated CoverageBuy$6.00High
5/24/2018UBS GroupInitiated CoverageOutperform$6.00High
2/8/2018Chardan CapitalLower TargetBuy ➝ Buy$30.00 ➝ $22.00Medium
(Data available from 10/6/2017 forward)

News Sentiment Rating

-0.77 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/10/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
5/9/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
6/8/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
7/8/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
8/7/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/6/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
10/6/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Very Positive

  • No very positive mentions tracked during this time.
VistaGen Therapeutics logo
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $0.16
Low: $0.16
High: $0.16

50 Day Range

MA: $0.17
Low: $0.14
High: $0.22

52 Week Range

Now: $0.16
Low: $0.14
High: $2.75

Volume

129,800 shs

Average Volume

9,923,763 shs

Market Capitalization

$32.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Frequently Asked Questions

What sell-side analysts currently cover shares of VistaGen Therapeutics?

The following sell-side analysts have issued research reports on VistaGen Therapeutics in the last twelve months: Jefferies Financial Group Inc., Maxim Group, Robert W. Baird, and William Blair.
View the latest analyst ratings for VTGN.

What is the current price target for VistaGen Therapeutics?

1 Wall Street analysts have set twelve-month price targets for VistaGen Therapeutics in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 5,603.4%. Robert W. Baird has the highest price target set, predicting VTGN will reach $9.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $9.00 for VistaGen Therapeutics in the next year.
View the latest price targets for VTGN.

What is the current consensus analyst rating for VistaGen Therapeutics?

VistaGen Therapeutics currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VTGN, but not buy more shares or sell existing shares.
View the latest ratings for VTGN.

What other companies compete with VistaGen Therapeutics?

How do I contact VistaGen Therapeutics' investor relations team?

VistaGen Therapeutics' physical mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 577-3600 and its investor relations email address is [email protected] The official website for VistaGen Therapeutics is www.vistagen.com. Learn More about contacing VistaGen Therapeutics investor relations.